Body Weight Gain Associated With Alectinib in Patients With ALK+ Non–Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials
Weight gain is under-reported as AE in trials. Actual weights showed ≥10% weight gain in 18% of patients. Clinicians should be aware of this AE, emphasizing the importance of timely identification and monitoring weight. Identifying predictors for weight gain remains challenging.
Authors
- Elisabeth F. C. van Rossum (ORCID: https://orcid.org/0000-0003-0120-4913)
- Marthe S. Paats (ORCID: https://orcid.org/0000-0003-1602-6195)
- Annemie M.W.J. Schols (ORCID: https://orcid.org/0000-0001-9878-0428)
- Anne‐Marie C. Dingemans (ORCID: https://orcid.org/0000-0001-6105-182X)
- Egbert F. Smit (ORCID: https://orcid.org/0000-0002-7329-6995)
- Sara J. Baart (ORCID: https://orcid.org/0000-0002-1427-901X)
- Barend J. Sikkema (ORCID: https://orcid.org/0009-0007-0537-3884)
- Ron H.J. Mathijssen (ORCID: https://orcid.org/0000-0001-5667-5697)
Institutions
- Leiden University Medical Center (NL)
- Erasmus MC (NL)
- Maastricht University (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1200/jco-24-01579
- Citations
- 7
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 2.93